Interactive role of breast cancer on dyslipidemia and hypertension metabolic risk according to treatment exposure and menopausal status
Article Category: Research Article
Published Online: May 02, 2021
Page range: 39 - 46
Received: Jun 30, 2018
Accepted: Apr 29, 2019
DOI: https://doi.org/10.2478/fco-2019-0018
Keywords
© 2021 Safaa A. Al-Zeidaneen et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Background
Breast cancer (BC) is the principal cause of cancer related deaths among women worldwide. The available evidence suggests that cardio-metabolic risk factors such as dyslipidemia and hypertension may contribute differently to breast cancer severity and pathogenesis. The aim of this study is to evaluate the interactive role of BC on dyslipidemia and HTN risk according to the type of treatment exposure and menopausal status.
Patients and methods
Observational experimental design implemented; permit to include 134 newly-diagnosed patients who were naïve to any type of treatment interventions and 262 recently-diagnosed patients during their first three months of treatments’ exposure including chemotherapy treatments. Patients with breast cancer were evaluated for dyslipidemia and hypertension biomarkers.
Results
About 5.0% of breast cancer patients had dyslipidemia. The prevalence of increased triglycerides and total cholesterol were more frequent (
Conclusions
Dyslipidemia and hypertension biomarkers were prevalent among breast cancer patients and the risk increased in postmenopausal women and after treatments’ exposure specially chemotherapy. This conclusion requires a closer attention by healthcare professionals in order to improve the outcomes after diagnosis and to enhance treatment exposure regarding postmenopausal women.